<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Heron Therapeuti — News on 6ix</title>
<link>https://6ix.com/company/heron-therapeuti</link>
<description>Latest news and press releases for Heron Therapeuti on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 26 Feb 2026 05:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/heron-therapeuti" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68357f8778dffbe2df0fb114.webp</url>
<title>Heron Therapeuti</title>
<link>https://6ix.com/company/heron-therapeuti</link>
</image>
<item>
<title>Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results</title>
<link>https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>– ZYNRELEF® and APONVIE® Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise– Achieved $154.9 Million in 2025 Net Revenue– Issues Full-Year</description>
</item>
<item>
<title>Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026</title>
<link>https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-on-thursday-february-26-2026</link>
<guid isPermaLink="true">https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-on-thursday-february-26-2026</guid>
<pubDate>Tue, 17 Feb 2026 13:30:00 GMT</pubDate>
<description>CARY, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Thursday, February 26, 2026, at 8:30 a.m. ET to report fourth quarter and full year 2025 financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the following registration link which will provide partici</description>
</item>
<item>
<title>Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth</title>
<link>https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-announces-preliminary-unaudited-142900661</link>
<guid isPermaLink="true">https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-announces-preliminary-unaudited-142900661</guid>
<pubDate>Fri, 09 Jan 2026 14:29:00 GMT</pubDate>
<description>CARY, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth quarter and full-year 2025 net revenue. “We are encouraged by the growth in Q4 2025, driven in particular by the momentum in our Acute Care franchise with ZYNRELEF® and APONVIE®,” said Craig Collard, Chief Executive Officer of Heron. “In addition to our revenue growth, we are extremely pleased wit</description>
</item>
<item>
<title>Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)</title>
<link>https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-announces-inclusion-aponvier-aprepitant-injectable-emulsion-newly</link>
<guid isPermaLink="true">https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-announces-inclusion-aponvier-aprepitant-injectable-emulsion-newly</guid>
<pubDate>Thu, 04 Dec 2025 05:00:00 GMT</pubDate>
<description>APONVIE, an aprepitant product, highlighted as the only FDA-approved IV formulation Neurokinin-1 (“NK-1”) antagonist indicated for the prevention of PONV in</description>
</item>
<item>
<title>Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress</title>
<link>https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-announces-q3-2025-financial-results-and-highlights-commercial</link>
<guid isPermaLink="true">https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-announces-q3-2025-financial-results-and-highlights-commercial</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>Generated Q3 2025 Net Revenue of $38.2 million and year-to-date revenue of $114.3 million; reaffirmed 2025 Net Revenue Guidance of $153 million - $163 million</description>
</item>
<item>
<title>Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors</title>
<link>https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-announces-appointment-thomas-cusack-board-directors-2025-10-29</link>
<guid isPermaLink="true">https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-announces-appointment-thomas-cusack-board-directors-2025-10-29</guid>
<pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
<description>CARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company,</description>
</item>
<item>
<title>Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025</title>
<link>https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-report-third-quarter-2025-financial-results-tuesday-november-4</link>
<guid isPermaLink="true">https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-report-third-quarter-2025-financial-results-tuesday-november-4</guid>
<pubDate>Tue, 21 Oct 2025 04:00:00 GMT</pubDate>
<description>CARY, N.C., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company,</description>
</item>
<item>
<title>Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value</title>
<link>https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-inc-adopts-tax-benefits-preservation-plan-protect-nol-assets-and</link>
<guid isPermaLink="true">https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-inc-adopts-tax-benefits-preservation-plan-protect-nol-assets-and</guid>
<pubDate>Fri, 15 Aug 2025 04:00:00 GMT</pubDate>
<description>CARY, N.C., Aug. 15, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today</description>
</item>
<item>
<title>Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile</title>
<link>https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-announces-comprehensive-capital-restructuring-support-growth-and</link>
<guid isPermaLink="true">https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-announces-comprehensive-capital-restructuring-support-growth-and</guid>
<pubDate>Fri, 08 Aug 2025 04:00:00 GMT</pubDate>
<description>CARY, N.C., Aug. 8, 2025 Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the</description>
</item>
<item>
<title>Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress</title>
<link>https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-announces-q2-2025-financial-results-and-highlights-commercial</link>
<guid isPermaLink="true">https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-announces-q2-2025-financial-results-and-highlights-commercial</guid>
<pubDate>Fri, 08 Aug 2025 04:00:00 GMT</pubDate>
<description>Generated Q2 2025 Net Revenue of $37.2 million and year-to-date revenue of $76.1 million; reaffirmed 2025 Net Revenue Guidance of $153 million - $163</description>
</item>
<item>
<title>Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025</title>
<link>https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-reschedules-second-quarter-2025-earnings-release-and-conference</link>
<guid isPermaLink="true">https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-reschedules-second-quarter-2025-earnings-release-and-conference</guid>
<pubDate>Fri, 08 Aug 2025 04:00:00 GMT</pubDate>
<description>CARY, N.C., Aug. 8, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today</description>
</item>
<item>
<title>Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025</title>
<link>https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-report-second-quarter-2025-financial-results-monday-august-11-2025</link>
<guid isPermaLink="true">https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-report-second-quarter-2025-financial-results-monday-august-11-2025</guid>
<pubDate>Mon, 28 Jul 2025 04:00:00 GMT</pubDate>
<description>CARY, N.C., July 28, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today</description>
</item>
<item>
<title>Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates</title>
<link>https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-announces-first-quarter-2025-financial-results-and-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-announces-first-quarter-2025-financial-results-and-highlights</guid>
<pubDate>Tue, 06 May 2025 04:00:00 GMT</pubDate>
<description>Generated Q1 2025 Net Revenue of $38.9 millionDelivered record Q1 2025 Adjusted EBITDA of $6.2 millionReached settlement with Mylan Pharmaceuticals, Inc.,</description>
</item>
<item>
<title>Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations</title>
<link>https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-announces-settlement-mylan-related-cinvantir-and-aponvier-patent</link>
<guid isPermaLink="true">https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-announces-settlement-mylan-related-cinvantir-and-aponvier-patent</guid>
<pubDate>Tue, 06 May 2025 04:00:00 GMT</pubDate>
<description>— Company Grants Mylan a License to Market Generic CINVANTI® and APONVIE® Beginning in June 2032 — CARY, N.C., May 6, 2025 /PRNewswire/ -- Heron Therapeutics,</description>
</item>
<item>
<title>Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer</title>
<link>https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-announces-appointment-mark-hensley-chief-operating-officer-2025-04</link>
<guid isPermaLink="true">https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-announces-appointment-mark-hensley-chief-operating-officer-2025-04</guid>
<pubDate>Mon, 28 Apr 2025 04:00:00 GMT</pubDate>
<description>CARY, N.C., April 28, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today</description>
</item>
<item>
<title>Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025</title>
<link>https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-report-first-quarter-2025-financial-results-tuesday-may-6-2025</link>
<guid isPermaLink="true">https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-report-first-quarter-2025-financial-results-tuesday-may-6-2025</guid>
<pubDate>Tue, 22 Apr 2025 04:00:00 GMT</pubDate>
<description>CARY, N.C., April 22, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today</description>
</item>
<item>
<title>Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates</title>
<link>https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-announces-fourth-quarter-and-full-year-2024-financial-results-and</link>
<guid isPermaLink="true">https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-announces-fourth-quarter-and-full-year-2024-financial-results-and</guid>
<pubDate>Thu, 27 Feb 2025 05:00:00 GMT</pubDate>
<description>Achieved Q4 2024 GAAP Net Income of $3.6 millionGenerated full-year 2024 Net Revenue of $144.2 million, up 14% year-over-yearDelivered full-year 2024 adjusted</description>
</item>
<item>
<title>Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025</title>
<link>https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-report-fourth-quarter-and-full-year-2024-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-report-fourth-quarter-and-full-year-2024-financial-results</guid>
<pubDate>Thu, 13 Feb 2025 05:00:00 GMT</pubDate>
<description>CARY, N.C., Feb. 13, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today</description>
</item>
<item>
<title>Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina</title>
<link>https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-announces-corporate-headquarters-relocation-cary-north-carolina</link>
<guid isPermaLink="true">https://6ix.com/company/heron-therapeuti/news/heron-therapeutics-announces-corporate-headquarters-relocation-cary-north-carolina</guid>
<pubDate>Mon, 23 Dec 2024 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Dec. 23, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company,</description>
</item>
<item>
<title>U.S. District Court Upholds Validity of CINVANTI® Patents</title>
<link>https://6ix.com/company/heron-therapeuti/news/us-district-court-upholds-validity-cinvantir-patents-2024-12-03</link>
<guid isPermaLink="true">https://6ix.com/company/heron-therapeuti/news/us-district-court-upholds-validity-cinvantir-patents-2024-12-03</guid>
<pubDate>Tue, 03 Dec 2024 05:00:00 GMT</pubDate>
<description>— Court Rules in Favor of Heron in Patent Lawsuit Against Fresenius Kabi USA, LLC — SAN DIEGO, Dec. 3, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq:</description>
</item>
</channel>
</rss>